🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zoster in Vulnerable Population Receiving ImmunOmodulaNt Therapies

Recruitingn/aAges 18 Years - 100 YearsAllFondazione IRCCS Policlinico San Matteo di Pavia
NCT07534007 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Varicella-zoster virus (VZV) is one of the eight herpesviruses that infect humans by manifesting as varicella. After primary infection VZV remains latent for life. In 30% of individuals the virus reactivates causing a secondary infection, herpes zoster (HZ). The most common complication of HZ is post-herpetic neuralgia (PHN) and, in severe cases, disseminated infection and death. The incidence of HZ increases as cell-mediated immunity (CMI) declines due to advanced age or the administration of immunomodulatory or immunosuppressive therapies. With the approval of the recombinant adjuvanted glycoprotein E (gE) vaccine (RZV; Shingrix™, GSK) also in immunocompromised individuals (IC) HZ is now considered a vaccine preventable disease. The development of novel biologic therapies has revolutionized the treatment of inflammatory skin conditions improving clinical responses in psoriasis and psor

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * • Patients over 18 years of age; * All genders are eligible for the study; * Patients with psoriasis receiving immunomodulant therapy (anti-TNF); * Patients with psoriasis who do not require immunomodulant therapy; * Patients with myelofibrosis receiving immunomodulant therapy (anti-JAK, such as Ruxolitinib); * Patients with myelofibrosis not receiving immunomodulant treatment; * Life expectancy (as estimated by the treating physician) ≥ 12 months or more; * Signed informed consent. Exclusion Criteria: * • At the end of the observation period; * In case of death; * If informed consent is revoked.
💊

What it tests

  • Not listed
📍

Where

1 site
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy